Management ChangeMay 28, 2026, 05:12 PM
Allogene Therapeutics Appoints Zachary Roberts as New CEO
AI Summary
Allogene Therapeutics, Inc. announced the appointment of Zachary Roberts, M.D., Ph.D. as its new President and Chief Executive Officer, effective July 1, 2026. Dr. Roberts, currently Executive Vice President, Research and Development, and Chief Medical Officer, will also join the Board of Directors. He replaces David Chang, M.D., Ph.D., who will step down from his executive roles on June 30, 2026, but will remain on the Board as a non-employee director. Dr. Roberts' compensation package includes an annual base salary of $680,000, a 60% target performance cash incentive, and equity awards.
Key Highlights
- Zachary Roberts, M.D., Ph.D. appointed President and Chief Executive Officer, effective July 1, 2026.
- Dr. Roberts also appointed to the Board as a Class I director, effective July 1, 2026.
- David Chang, M.D., Ph.D. will conclude service as President and CEO on June 30, 2026.
- Dr. Chang will remain on the Board as a non-employee director.
- Dr. Roberts' annual base salary set at $680,000.
- Dr. Roberts' annual target performance cash incentive is 60% of his base salary.
- Dr. Roberts granted an option to purchase 476,190 shares of common stock.
- Dr. Roberts granted a restricted stock unit of 134,530 shares of common stock.
Price Impact
More from ALLO